Home > Quotes > CELG
CELG

Celgene Corporation Stock Quote & Summary Data

$122.58
*  
1.06
  negative  
0.86%
Get CELG Alerts
*Delayed - data as of May 24, 2013 
Exchange: NASDAQ
Industry: Consumer Durables
Community Rating:
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored

Best Bid /Ask: N/A / N/A
1 Year Target: 133.5
Today's High/Low:  / 
Share Volume:
50 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume. 3,234,597
Previous Close: $ 123.64
52 Week High /Low: $ 131.819 / $ 58.53
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. 51,130,873,231
P/E Ratio: 37.26
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. 23.15
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ 3.29
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Beta 1.28
NASDAQ Official Open Price NASDAQ Official Opening Price: This process identifies the NASDAQ-specific opening prices for NASDAQ-listed issues. $ 122.61
Date of Open Price This field refers to the date the NASDAQ Official Open Price was disseminated for a given stock. It is possible that the date will not be from the current trading day; this indicates that the stock didn't trade on NASDAQ during the current trading day. The NASDAQ Official Open Price is updated only when the stock is traded on NASDAQ. May 24, 2013
NASDAQ Official Close Price The NASDAQ® Official Closing Price (NOCP) is a process for identifying the NASDAQ market-specific closing price for NASDAQ-listed issues. The NOCP replaces the NASDAQ market-specific closing price that was based solely on the last reported NASDAQ trade. Subject to review by NASDAQ MarketWatch, the NOCP will equal the normalized price of the last trade reported to NASDAQ’s proprietary trade reporting system—Automated Confirmation Transaction ServiceSM (ACTSM—with a last sale eligible sale condition modifier as of 4:00:02 p.m., US Eastern Time. "Normalizing" the NOCP means it will be adjusted to the nearest prevailing inside quote whenever the last sale is reported away from the inside market. Market participants, data distributors and investors will be provided with the NOCP for all NASDAQ Global Select MarketSM, NASDAQ Global MarketSM and NASDAQ Capital MarketSM securities. $ 122.58
Date of Close Price This field refers to the date the NOCP was disseminated for a given stock. It is possible that the date will not be from the prior day; this indicates that the stock didn't trade on NASDAQ on the prior day. The NOCP is updated only when the stock is traded on NASDAQ. May 24, 2013
Community Sentiment

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

ETFs with CELG as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
7.17% iShares NASDAQ Biotechnology Index Fund (IBB) +46.33  (34.33%)
5.39% First Trust Amex Biotechnology Index Fund (FBT) +14.07  (31.13%)
4.12% Columbia Select Large Cap Growth ETF (RWG) +5.98  (20.54%)
3.34% First Trust Mega Cap Alphadex Fund (FMK) +3.58  (19.02%)
3.27% SPDR Series Trust SPDR S&P Biotech ETF (XBI) +15.12  (17.55%)

We make it easy to follow the leaders. PowerShares QQQ. 100 companies at the top of innovation in one fund.


*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.

**Green highlights the top performing ETF by % change in the past 100 days.

 Company Description (as filed with the SEC)

Celgene Corporation (collectively with its subsidiaries, "we," "our," "us," "Celgene" or the "Company") is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. We are dedicated to innovative research and development designed to bring new therapies to market and are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Celgene was incorporated in the State of Delaware in 1986. Our primary commercial stage products include REVLIMID®, VIDAZA®, ABRAXANE®, THALOMID® (inclusive of Thalidomide Celgene®), and ISTODAX®. POMALYST® was approved by the U.S.  ... More ...  



News Headlines for CELG

Encouraging News for Peregrine Pharma - Analyst Blog
5/24/2013 12:28:57 PM - Zacks.com
Investing In Cancer Research Is Worth The Risk: Echo He
5/24/2013 11:59:00 AM - Seeking Alpha
Priority FDA Review for Celgene's Abraxane - Analyst Blog
5/24/2013 11:28:02 AM - Zacks.com
Encouraging News for Peregrine Pharma - Analyst Blog
5/23/2013 7:26:41 PM - Zacks.com
NPS Pharma Prices Offering - Analyst Blog
5/23/2013 7:25:47 PM - Zacks.com
 

Consensus Recommendation